PEN vs VRDN
Penumbra, Inc. vs Viridian Therapeutics, Inc. — AI-powered side-by-side comparison
PEN
Penumbra, Inc.
67
Buy
VS
VRDN
Viridian Therapeutics, Inc.
64
Buy
| Metric | PEN | VRDN |
|---|
| AI Score |
67
|
64
|
| Price |
$326.07
|
$23.00
|
| P/E Ratio |
79.78×
|
-6.28×
|
| ROE |
12.4%
|
-47.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
67.8%
|
99.4%
|
| Debt / Equity |
0.14×
|
0.37×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
79.6
|
74.5
|
| Beta |
0.701
|
0.94
|
| Expected Upside |
+6.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for PEN versus VRDN.
PEN leads by 3 points.
PEN scores 67/100 (Buy) versus VRDN at 64/100 (Buy).
PEN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 consecutive earnings misses -- execution concerns. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- 2 consecutive earnings misses -- execution concerns — Growth
- RSI at 80 is in overbought territory — Technical
VRDN Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 23220.3% YoY -- genuine top-line momentum — Growth
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 4.1x prices in significant intangible value — Value
- ROE of only -61.4% -- cheap may mean cheap for a reason — Value
- RSI at 74 is in overbought territory — Technical